The stock of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) is a huge mover today! The stock increased 3.78% or $0.35 during the last trading session, hitting $9.61. About 151,384 shares traded hands. Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has risen 61.61% since February 29, 2016 and is uptrending. It has outperformed by 49.39% the S&P500.
The move comes after 8 months positive chart setup for the $342.47M company. It was reported on Oct, 4 by Barchart.com. We have $15.38 PT which if reached, will make NASDAQ:FOMX worth $205.48 million more.
Analysts await Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) to report earnings on November, 9. They expect $-0.26 EPS, down 136.36% or $0.15 from last year’s $-0.11 per share. After $-0.27 actual EPS reported by Foamix Pharmaceuticals Ltd for the previous quarter, Wall Street now forecasts -3.70% EPS growth.
According to Zacks Investment Research, “Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company’s lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel.”
More notable recent Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) news were published by: Prnewswire.com which released: “Foamix Pharmaceuticals Ltd. Announces Proposed Follow-on Offering of Ordinary …” on September 27, 2016, also Marketwatch.com with their article: “Virtual Stock Exchange” published on September 19, 2014, Quotes.Wsj.com published: “News Foamix Pharmaceuticals Ltd.FOMX” on September 13, 2014. More interesting news about Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) were released by: Prnewswire.com and their article: “Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX …” published on September 12, 2016 as well as Schaeffersresearch.com‘s news article titled: “Analyst Update: Foamix Pharmaceuticals Ltd, Jazz Pharmaceuticals plc, and …” with publication date: August 10, 2016.
FOMX Company Profile
Foamix Pharmaceuticals Ltd., incorporated on January 19, 2003, is a clinical-stage specialty pharmaceutical company. The Firm is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Firm operates in the segment of development and commercialization of foam formulations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.